Capricor Therapeutics Says Duchenne Muscular Dystrophy Candidate Shows Sustained Cardiac, Skeletal Benefits After 3 Years
Portfolio Pulse from Vandana Singh
Capricor Therapeutics announced positive 3-year results from its HOPE-2 study for deramiocel, showing sustained cardiac and skeletal benefits in treating Duchenne muscular dystrophy. The study highlights improvements in cardiac function and a favorable safety profile, boosting CAPR stock by 8.05%.
October 11, 2024 | 4:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Capricor Therapeutics' deramiocel shows sustained cardiac and skeletal benefits in a 3-year study for Duchenne muscular dystrophy, leading to an 8.05% rise in CAPR stock.
The positive 3-year results from the HOPE-2 study for deramiocel, showing improvements in cardiac function and a favorable safety profile, are significant for Capricor Therapeutics. This news is likely to boost investor confidence and positively impact CAPR's stock price in the short term, as evidenced by the 8.05% increase.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100